Lttl vs yourEra

What we like

• Publishes its entire price ladder — every product, every term, every rung — in the public page source, each one labeled with what it bills (“$199/mo every month” beside “$1,548 annually”), with no intake quiz standing between you and the number
• A genuine month-to-month rung exists and is purchasable for every product, with no contracts and no minimum term, so the prepay ladder is an optional discount rather than the only way in
• Both molecules across three routes — injection, orally disintegrating tablet, and lower-dose microdose lines sold as their own products with their own published ladders rather than quoted at the full-dose price

The caveats

• –All fourteen product cards hardcode “from $129/mo”. For semaglutide that is the twelve-month rung billed $1,548 up front; for tirzepatide, the semaglutide ODT and the microdose ODT it is a price purchasable at no tier at all
• –The month-to-month rates are roughly 40% above the advertised figure — $199 for semaglutide and $279 for tirzepatide against the $129 on every card
• –Names no medical director and no prescribing clinician, offers and requires no labs or bloodwork, and carries no third-party certification such as LegitScript

What we like

• Publicly listed pricing on both molecules — semaglutide from $199/mo and tirzepatide from $299/mo — while many compounders hide price behind a quiz
• Fuller menu beyond GLP-1: NAD+ and microdosing protocols, plus an optional membership adding 1:1 coaching, a nutritionist, and an at-home lab draw
• Markets a 50-state licensed-clinician network, no insurance required, with HSA/FSA accepted

The caveats

• –Compounded semaglutide and tirzepatide are not FDA-approved the way brand Wegovy, Ozempic, or Zepbound are, and compounding access can tighten as brand shortages resolve
• –Mid-market pricing that sits above the cheapest compounders (roughly $99–$150)
• –Injectable only — no oral route and no brand-name lane